Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo Life Science Investing
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition Life Science Investing
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 Life Science Investing
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response Life Science Investing
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 Life Science Investing
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones Life Science Investing
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies Life Science Investing
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco Life Science Investing
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering Life Science Investing
Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference Life Science Investing